Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Short

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Haematologica|July 2, 2026
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemiaThura Win Htut, Jeannot Kekedjian, Nicholas Short, et al.
American Journal of Hematology|October 10, 2019
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationSamer A Srour, Rima M Saliba, Maria C B Bittencourt, et al.
Blood Cancer Journal|March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyAlex Bataller, Koji Sasaki, Samuel Urrutia, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Leukemia|July 21, 2025
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapyAlexandre Bazinet, Sanam Loghavi, Yue Wei, et al.
Blood Cancer Journal|March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosisRashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Blood Cancer Journal|March 28, 2026
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromesAlexandre Bazinet, Alex Bataller, Kelly Chien, et al.
Research Square|March 3, 2023
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analysesMarina Konopleva, Courtney DiNardo, Tushar Bhagat, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Haematologica|July 2, 2026
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemiaThura Win Htut, Jeannot Kekedjian, Nicholas Short, et al.
American Journal of Hematology|October 10, 2019
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationSamer A Srour, Rima M Saliba, Maria C B Bittencourt, et al.
Blood Cancer Journal|March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyAlex Bataller, Koji Sasaki, Samuel Urrutia, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Leukemia|July 21, 2025
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapyAlexandre Bazinet, Sanam Loghavi, Yue Wei, et al.
Blood Cancer Journal|March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosisRashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Blood Cancer Journal|March 28, 2026
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromesAlexandre Bazinet, Alex Bataller, Kelly Chien, et al.
Research Square|March 3, 2023
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analysesMarina Konopleva, Courtney DiNardo, Tushar Bhagat, et al.
Pageof 5